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1. Introduction 
Breast cancer is one of the most life threatening risks in women's life. In spite of considerable 
progress in its understanding and challenges, treatment is not yet the correct word to apply 
on this disease and losing life is the most foreseeing adventure in many patients. Although 
new gene therapy based approaches are looking for the cure of breast malignant cells, but 
using cytotoxic agents is currently the main chemotherapy approach to fight this problem. 
Effective chemotherapy treatment of breast cancer requires targeting the pathways that 
support the cell growth and proliferation. A good in vitro investigational model is essential 
to understand the process of carcinogenesis, risk and hazard mechanism of carcinogens, 
protection from carcinogens, mode of action and efficacy of novel and even in practice 
chemotherapeutic agents. The main part for any of these laboratory models is suitable cell 
lines to properly address the problem and goal of investigation. 
Estrogen Receptor (ER) is considered to cause different growth responses in ER-positive, 
normal, preneoplastic and neoplastic cells (DuMond et al., 2001; Roy & Cai, 2002; Welshons 
et al., 2003). One of the most significant researches in cancer treatment has been based on 
designing and studying the ER-antagonism effects of molecules on cells. This is important to 
select suitable cell lines for in vitro drug discoveries studies. Table 1 shows a list of epithelial 
breast cell lines with different expression in estrogen receptor. 
Intracellular enzymes responsible for the different consequences of receptors stimulations 
and signaling cascades are also under big considerations in fighting breast cancer cells. 
Dihydrofolate reductase (DHFR; tetrahydrofolate dehydrogenase; 5,6,7,8-tetrahydrofolate-
NADP+ oxidoreductase) is an example of pivotal importance in biochemistry and medicinal 
chemistry. DHFR catalyzes the reduction of folate or 7,8-dihydrofolate to tetrahydrofolate 
and intimately couples with thymidylate synthase (TS). Reduced folates are carriers of one- 
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Cell line Suitable 
growth 
media 
Kinds of receptor Oncogene considerations 
ZR-75-1 RPMI-1640 
& 10% FBS 
Estrogen receptor  
 
 
MCF-7 DMEM:F12 
& 10% FBS 
-Estrogen receptor  
UACC-3199 Leibovitz's 
L-15 & 10% 
FBS 
-Epidermal growth factor 
receptor  expressed 
-Estrogen receptor negative, 
-Progesterone receptor negative
 
HCC1954 RPMI-1640 
& 10% FBS 
-Estrogen receptor  
-Progesterone receptor 
her2/neu + (over expressed) 
HCC1500 RPMI-1640 
& 10% FBS 
-Estrogen receptor  
-Progesterone receptor 
Negative for expression of 
Her2-neu, positive for 
expression of p53 
HCC70 RPMI-1640 
& 10% FBS 
-Progesterone receptor negative Negative for expression of 
Her2/neu, positive for 
expression of p53 
HCC1008 DMEM:F12 
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Positive for expression of Her2-
neu, positive for expression of 
p53 
HCC1143 RPMI-1640 
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Negative for expression of 
Her2/neu, positive for 
expression of p53 
HCC38 RPMI-1640 
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Negative for expression of 
Her2/neu, positive for 
expression of p53 
UACC-893 Leibovitz's 
L-15 & 10% 
FBS 
-Estrogen receptor negative 
-Progesterone receptor negative
-P glycoprotein negative  
The cells exhibit a 20 fold 
amplification of the HER-
2/neu oncogene sequence 
HCC1395 
 
RPMI-1640 
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Negative for expression of 
Her2/neu, 
Positive for expression of p53 
HCC1419 
& 
HCC202 
RPMI-1640 
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Positive for expression of 
Her2/neu, 
Negative for expression of p53 
HCC1806 & 
HCC1599 
RPMI-1640 
& 10% FBS 
-Progesterone receptor 
negative, 
-Estrogen receptor negative 
Negative for expression of 
Her2-neu, 
Negative for expression of p53 
HCC1937 RPMI-1640 
& 10% FBS 
-Estrogen receptor negative 
-Progesterone receptor negative
BRCA1 (mutated, insertion C 
at nucleotide 5382), 
Negative for expression of 
Her2-neu, 
Negative for expression  
of p53 
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Cell line Suitable 
growth 
media 
Kinds of receptor Oncogene considerations 
HCC2157 ACL-4 
medium  
& 10% FBS 
-Estrogen receptor negative, 
-Progesterone receptor negative
Positive for expression of  
Her2-neu , Positive  for 
expression of p53 
Table 1. List of breast cell lines with different expression in estrogen receptor. 
carbon fragments; hence they are important cofactors in the biosynthesis of nucleic acids 
and amino acids. The inhibition of DHFR or TS activity in the absence of salvage leads to 
‘thymineless’ death.  
There are some other enzymes which came into special consideration in cancer 
development, particularly in the breast cancer. Cyclooxygenase-2 is an example that over 
expresses in several epithelial tumors including breast cancer. Preclinical evidence favors an 
anti tumor role for COX inhibitors in breast cancer because there is a clear relationship 
between tissue prostaglandin levels in human breast tumors and the development of 
metastasis and patient survival (Arun & Goss, 2004). Selective COX-2 inhibitors can prevent 
mammary tumors from developing cancer in experimental animals. Celecoxib (a COX-2 
inhibitor) has proven to minimize the progression of carcinogen-induced mammary tumors 
(Arun et al., 2001). A good cell line to clearly address alterations in above mentioned 
systems is also critical for challenging breast cancer cells in vitro.  
A trustable measurement approach to detect results of the application of under-
investigation agents on cells is very much important. Different methods have been applied 
to investigate cell alterations and ultimately cell death resulted from cancer chemotherapy 
and cytotoxic agents. Each of them has advantages and disadvantages in different situations 
and for different purposes. Misuse of any of these methods for the detection of the 
cytotoxicity of different agents on different cell lines is one of the main problems of many 
publications for years. These techniques usually look at the viability, morphology and/or 
biochemical function of various cellular functions. Table 2 lists some of the most popular 
methods used to measure the cytotoxicity of agents in cellular experiments. 
A precise and accurate investigation is one that selects the best possible measurement 
method on the best possible cell line in the most optimal situation for the best possible 
conclusion. Cellular investigations to look for new anti-breast cancer agents rely on these 
bases. MCF-7 proves to be a suitable model cell line for breast cancer investigations 
worldwide. This is a well known breast cancer cell line derived from a 69 years old 
Caucasian female. MCF-7 cell line presents most of characteristics of differentiated 
mammary epithelium tissues including those of expressing estradiol and estrogenic 
receptors features (Brandes & Hermonat, 1983). Here, we are summarizing some of our 
results using this cell line to search for novel anti-breast cancer agents, with emphasis and 
conclusive remarks on the good laboratory practice. 
2. Targeting estrogen receptors 
Estrogens are known to play an important role in the regulation of the development and 
maintenance of the female reproductive system, in particular of the uterus, ovaries and 
breast. Moreover, estrogens are involved in the growth and/or function of several other 
tissues such as bone, liver, brain, and the cardiovascular system (Ciocca & Roig, 1995).  
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Method Measurement criteria 
Sample methodology 
references 
Vital dyes (Methylene blue, 
Trypan blue, Phenol red, …)
Cell membrane integrity 
(Shirazi et al., 2005; 
Shokrzadeh et al., 2006) 
Clonogenic assay, 
cell numbers 
Cellular proliferation 
(Shirazi & Eftekhari, 2004; 
Shirazi et al., 1996) 
MTT and XTT 
Function of mitochondrial 
enzymes 
(Shirazi et al., 2004; 
Tamaddon et al., 2007) 
Thymidine assay, 
Bromodeoxyuridine 
Cellular DNA synthesis 
(Hammers et al., 2002; 
Maghni et al., 1999; 
Raaphorst et al., 1998; 
Yokochi & Gilbert, 2007) 
Blotting techniques 
DNA, RNA and Protein 
synthesis machinery 
(Ko et al., 1993; Singh et 
al., 2008; Skliris et al., 
2002) 
Flowcytometry 
Population based cell cycle 
analysis, Individual cell content 
and biophysical status 
(Lukyanova et al., 2009; 
Niknafs & Shirazi, 2002; 
Skliris et al., 2002;) 
Light and electron 
microscopes 
Cellular morphology and 
structural features 
(Lukyanova et al., 2009; 
Russo et al., 1977;  
Vic et al., 1982) 
Table 2. Different popular methods to measure cellular alterations after exposure to 
cytotoxic agents. 
Figure 1 represents the general effects of estradiol (as a proliferative estrogen receptor 
stimulant agent) and tamoxifen (as an estrogen receptor blocking agent) on the growth 
curve of MCF-7 cell line. To obtain this, 50,000 cells were seeded in four series of cell 
culture petri dishes and incubated in phenol red-free RPMI media supplemented with 
10% fetal bovine serum for 7 days. From the beginning, three different series of petri 
dishes were selected for the experiments; estradiol was added into the media of one 
series, tamoxifen was added to the media of the second series and a mix of these two 
agents was added to the third series of petri dishes. Cells in each perti dish were counted 
for seven consecutive days as the presentation of cell proliferation in control, estradiol 
exposed, tamoxifen exposed, and affected by both of estradiol and tamoxifen agents. As is 
seen in figure 1, estradiol has a significant effect to promote the growth of MCF-7 breast 
cancer cells compared to the control cells. MCF-7 cells, however, are arrested for at least 
five days before being able to start a significant proliferation after the exposure to the 
estrogen-blocking agent of tamoxifen. This block is effective enough to prevent the 
stimulating effect of estradiol when cells are exposed to both agents simultaneously. This 
experiment would further emphasize on the stimulating effect of estrogen receptors in 
breast cancer progression. 
Several studies have established that estrogens are predominantly involved in the initiation 
and proliferation of breast cancer. Lots of efforts are now being devoted to block estrogen 
formation and action as an anticancer strategy (Clemons & Goss, 2001; Jensen et al., 2001; 
Nelson et al., 2009). This has led to the development of compounds termed Selective 
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Estrogen Receptor Modulators (SERMs), which function as estrogen agonists in some tissues 
(bone, brain and the cardiovascular system) but as antagonists in others (uterus and breast). 
Estrogen action is mediated through two Estrogen Receptor (ER) subtypes, ER┙ and ER┚, 
which have distinct target tissue distributions and functional activities (Gustafsson et al., 
2003; Matthews & Gustafsson, 2003; Välimaa et al., 2004). ER┙ is predominantly found in the 
uterus, bone, cardiovascular tissue, and liver and is the predominant ER expressed in breast 
cancer. ER┚ is expressed in many tissues including prostate, breast, vascular endothelium, 
and ovary. The precise function of ER┚ and its role in breast is not clear (Fox et al., 2008; 
Novelli et al., 2008). Recent studies indicate that ER┚ expression may have a potential 
protective effect on normal cells against ER┙ induced hyperproliferation (Bardin et al., 
2004). 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Stimulation and inhibition of MCF-7 breast cancer cell line exposed to estradiol, 
tamoxifen and mix of these two agents for 7 days in phenol red-free RPMI media incubated 
in 37°C and 5% CO2 humified incubator. 
Estrogen receptors can bind a variety of steroidal and non-steroidal ligands. Tamoxifen was 
the first SERM approved for the treatment of breast cancer (Jordan, 1988). The search for 
better SERMs has driven efforts to increase the chemical diversity of these compounds, 
especially the non-steroidal ones (Meegan & Lloyd, 2003). Figure 2 shows the structures of 
tamoxifen and other known SERMs such as ralolxifen and rasofoxifen. 
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Fig. 2. Chemical structures of some known Selective Estrogen Receptor Modulators 
(SERMs). 
Structure-activity relationship (SAR) studies and molecular modeling studies center lead to 
the design of novel structures containing 1,2,3-triarylpropenone scaffold to act as potential 
SERMs and anti breast cancer agents with a unique structure as is shown in Figure 3. 
 
R
O
X
R: alkoxy heterocycle groups
X: different chemical groups
Componds a-d
 
Fig. 3. The general model of 1,2,3-triarylpropenone scaffold as a novel potential SERMs and 
anti breast cancer agents. 
The compounds a to d have been synthesized and undergone biological evaluations in an in 
vitro cellular system using MCF-7 breast cancer cell line as the model. The anti-proliferative 
activities of these compounds were determined using MTT assay. To do so, a ten thousands 
cells were seeded in phenol red-free RPMI-1640 medium supplemented with 10% FBS in 
each well of 96-well micro culture plates and incubated for 24 hours at 37 ºC in a 5% CO2 
incubator. Different concentrations of each compound were added to the wells with 
respective vehicle control for 72 hours. Media were then removed and MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added to each well. Formazon 
crystals were dissolved in 200 µL of DMSO after 4.5 hours incubation and the dye 
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absorbance for each well was measured at 540 nm. A comparison of absorbance in each well 
containing different concentrations of each compound to the control wells could easily 
represent the number of live cells in that well as a result of the cell mitochondrial function 
(Zhu et al., 2006). 
The results of anti-proliferative MTT assays of compounds a to d on MCF-7 breast cancer 
cells are shown in the graphs below (Figure 4). Start point (time 0) is shifted in each set of 
figures for a better clarification of the shape and trends of graphs in case of compounds a, b 
and d. These graphs show the comparative cytotoxic and antiproliferative effects of all of 
these compounds on MCF-7 cell line. 
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Fig. 4. Cytotoxic effects of tamoxifen and compounds a to d on MCF-7 cell line presents a 
comparable antiproliferative effects on cancer cells. 
Estrogen receptor binding studies were carried out for the compounds with ER┙ and ER┚ 
using a fluorescence polarization procedure to prove the stimulatory and inhibitory 
mechanism being through the estrogenic receptors (data not shown). The compounds were 
active on ER┙ at nanomolar concentrations and on ER┚ at micromolar concentrations.  
Therefore compounds a to d selectively bind to ER┙. 
Interestingly, clonogenic assays on MCF-7 cell line after exposure to these compounds fail to 
present solid and reliable growth inhibitory effects. Figure 5 shows some graphs resulted 
from the same exposure strategy of above-mentioned compounds on MCF-7, but using the 
clonogenic methodology to compare the results. A clear weakness is evident in these graphs 
preventing from any conclusive interpretation of results. We will further discuss this finding 
at the end of this chapter.   
3. Targeting COX-2 enzyme 
There is considerable evidence to suggest that prostaglandins play an important role in the 
development and growth of cancer. The enzyme cyclooxygenase (COX) catalyses the 
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conversion of arachidonic acid to prostaglandins (Abou-Issa et al., 2001). There has been a 
considerable amount of interest in recent years to take advantage of COX inhibitors 
specifically COX-2 inhibitors in prevention and treatment of malignancies (Talley et al., 
2000; Zarghi et al., 2006). Majority of COX-2 inhibitors belong to a class of diaryl 
heterocycles that possess vicinal diaryl substitution attached to mono, bicyclic or tricyclic 
central rings (Penning et al., 1997; Prasit et al., 1999; Riendeau et al., 2001). 
As a part of ongoing program to design new types of selective COX-2 inhibitors, our center 
has synthesized novel COX-2 inhibitor derivatives having a new tricyclic central ring 
scaffold and different substituents at the N-3 as is shown in figure 5. 
 
 
Fig. 5. Central structure of novel COX-2 inhibitors. 
The nature and size of substituent attached to N-3 influenced both selectivity and potency 
for COX-2 inhibitory activity. Two different compounds of C1 and C2 with different N-3 
substituent have been applied to MCF-7 cell line for the evaluation of anticancer effects, 
using clonogenic assay. MCF-7 cells were seeded for the clonogenic assay in 12-well plates 
at 150 cells per well for 24 hours. These cells were then exposed to C1 and C2 derivatives for 
24 hours. Media was then changed to fresh media without these compounds and plates 
remained in incubator for couple of days until most of colonies in the control wells 
contained more than 50 cells. Media was then excluded and cells were fixed with 96% 
ethanol and stained using trypan blue. Plates were washed and percentages of colonies in 
different wells were compared to controls (Shirazi et al., 2005). 
 
    
Fig. 6. Cytotoxicity of two novel COX-2 inhibitors of C1 and C2 on MCF-7 cell line using 
clonogenic assay. 
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As is shown in figure 6, both compounds have acceptable cytotoxicity effects with C1 being 
stronger. However, the same experiment has been conducted using the same cell line and 
the same concentrations of C1 and C2 compounds but using MTT assay. MTT failed to 
present any cytotoxicity for these compounds on MCF-7 cell line as is shown in figure 7. 
 
    
Fig. 7. MTT based cytotoxicity measurement of two novel COX-2 inhibitors of C1 and C2 on 
MCF-7 cell line. 
Failure of one experiment using a technique in spite of success for the other technique in 
acquiring result is a considerable phenomena in cellular investigation on cytotoxic agents 
and will be discussed later on in this chapter. 
4. Targeting dihydrofolate reductase (DHFR) enzyme  
Inhibitors of DHFR are classified as either ‘classical’ or ‘non-classical’ antifolates. The 
‘classical’ antifolates are characterized by a p-aminobenzoylglutamic acid side-chain in the 
molecule and thus closely resemble folic acid itself. Methotraxate (MTX) is the most well 
known drug among the ‘classical’ antifolates. Compounds classified as ‘non-classical’ 
inhibitors of DHFR do not possess the p-aminobenzoylglutamic acid side-chain but rather 
have a lipophilic side-chain. MTX serves as an antimetabolite, which means that it has a 
similar structure to that of a cell metabolite, resulting in a compound with a biological 
activity that is antagonistic to that of the metabolite, which in this case is folic acid (Barnhart  
et al., 2001; Takemura et al., 1997). 
New, more lipophilic antifolates have been developed in an attempt to circumvent the 
mechanisms of resistance, such as decreased active transport, decreased polyglutamation, 
DHFR mutations and so on (Assaraf, 2007; Gangjee  et al., 2006; Takemura et al., 1997). In a 
series of synthesized compounds for this purpose in our center the pyrimidine ring 
remained (figure 8) and the side-chain attachment at the position 2 was replaced with 
different substituent. 
 
N
N
NH2
H2N S
R2
 
Fig. 8. The central structure of novel DHFR inhibitors. 
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Fig. 9. Cytotoxicity measurement of seven selected DHFR inhibitors on MCF-7 cell line 
resulted from clonogenic assay. 
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These modified antifolates differ from the traditional ‘classical' analogues by increased 
potency, greater lipid solubility, or improved cellular uptake. Although being very effective 
as inhibitors, problems still remain with respect to the issue of toxicity due to the lack of 
selectivity (Cody et al., 2003; Graffner-Nordberg et al., 2004; McGuire, 2003). To evaluate the 
cytotoxic potency of these compounds, we have used the clonogenic assay. MCF-7 cells 
were plated in 6-well plates (200 cells/well) for 24 hours before treatment with the test 
compounds to allow the attachment of cells to the wells surface. Seven different 
concentrations of each compound, doxorubicin (as reference), and 0.5% DMSO (applied 
solvent to dissolve the compound) were added to the monolayer cells in triplicates. The 
plates were then incubated for 10 days at 37 ºC in atmosphere of 5% CO2. The media were 
removed after 10 days and the colonies were stained with a solution of 0.5% crystal violet in 
ethanol for 10 minutes and the number of colonies containing more than 50 cells was 
counted under microscope. The relation between the number of the colonies (as a 
percentage to the control containing 0.5% DMSO) and the concentrations of each compound 
were plotted to get survival curve of the tumor cell line and IC50 values were calculated. 
Cellular viability test results for some examples of this series of novel DHFR inhibitors are 
presented in figure 9. 
5. Discussion 
Human mammary gland adenocarcinoma MCF-7 cell line (ATCC HTB-22TM) is proven to be 
a good breast tissue model for anticancer drugs investigations in our experiments. However, 
selection of a suitable cell line is only a part of a successful and meaningful in vitro cellular 
examination of potential anticancer agents. Many different factors might very much 
influence the final outcome of the evaluation of a medication in a cellular experiment, 
among them are the cell culture media and its components during the time of drug exposure 
and afterward, exposure time, drug solvent, volume of drug solution to be added to the cell 
culture media, the proper use of agonists and antagonists for the purpose of elaborations on 
the results and making a meaningful conclusion, methodology of cellular viability 
assessment, and the most important factor; the personnel who run the experiment. We are 
not going to extensively discuss all of these parameters and their specific influences on the 
final result and conclusion, but the limited examples presented in this chapter may be 
sufficient to raise awareness for a good cellular practice. 
The importance of a suitable protocol for the measurement of survival percentage (live 
versus death) of cells is underestimated in many of experiments. Selection of the method in 
many instances is easily a matter of facility, budget and distributing companies' 
advertisements in the region. However, one should notice that for many known and 
unknown reasons, various methods of MTT, XTT, SRB, fluorescence dye staining and so on 
might work or not for different experiments. The main reason might well be the cellular 
measurement criteria for any of these methods. One should keep in mind that although 
mitochondria is the heart of cellular energy system, but MTT and XTT experiments would 
only measure the functionality of a mitochondrial enzyme (Cody et al., 2003; Marshall et al., 
1995; Scudiero et al., 1988) and would not necessarily reflect the cell viability. The same is 
very much true for many of staining methods e.g Annexin V which is an indication of cell 
membrane flip-flop that would most properly occur during the process of apoptosis 
(Kolodgie et al., 2003; Van Heerde et al., 2000). Both of these methods are extensively used 
for the measurement of the cytotoxicity of many different agents. The chemical structure of 
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under investigation compound, its solvent, its cellular site of action, the exposure time, the 
lag time from the beginning of exposure to the start of measurement, and even the selection 
of cell line might dramatically alter the final survival curve. Methotrexate is a good example 
of MTT limitation in cytotoxicity measurement (Haber et al., 1993) and colleagues have 
shown that MTT protocol is not able to assess the cytotoxicity of this anticancer agent on 
various cells including MCF-7. Our experiments on other novel DHFR inhibitors have also 
proven the same conclusion when MTT results were not conclusive while the clonogenic g 
assay could easily provide a meaningful dose-response result. Figure 10 shows a 
comparison of MTT versus clonogenic assay for the measurement of methotrexate as well as 
some other novel DHFR inhibitors. As is shown in this figure, clonogenic assay was more 
successful in determining the LD50 of these compounds in MCF-7 cell line, but not the MTT 
protocol. Alteration of the exposure time and lag time between the addition of drugs and 
start of MTT assay, media components and calculation method were not helpful to provide 
a conclusive survival curve using this method (Data are not shown). 
 
   
Fig. 10. Comparison of clonogenic versus MTT assays for the measurement of methotrexate 
and some other novel DHFR inhibitors. 
Clonogenic assay is usually considered as a final answer for drugs cytotoxicity because of its 
long waiting time to acquire result. A minimum of five to six cellular doubling times to look 
at results in clonogenic assay might well overcome all cellular adventures of arrest, repair, 
detoxification and exertion pumps influences on drug cellular mortality which might affect 
the result of cross sectional measurement methods like MTT and Annexin V. Figure 7 is 
another example of the limitation of these type of experiments in some instances in 
comparison with the clonogenic assay. Clonogenic assay, however, would surprisingly fail 
to present a meaningful graph of cytotoxicity after exposure to some compounds.  
There are many different mechanisms which might cause these differences in the result of 
the viability measurement using different methodologies. Cellular target of the test 
compound and the cellular repair system are two of the most possible explanation. 
Rosenberg confusion about the effects of electric field on the cells resulted in cisplatin 
identification and later use as a very important and most used anticancer drug in many 
different kinds of malignancies including the breast cancer (Rosenberg et al., 1969). Cells in 
Rosenberg set up did not die, rather changed shape and remained alive for a long time 
(Rosenberg, 1985, 1977). Cisplatin, like many other anti-mitotic agents, does not kill cells 
right after exposure. Its principle mechanism of action is on the DNA and thus while 
stopping DNA synthesis and cell proliferation, won't affect the mitochondrial action and cell 
membrane integrity. That is why, while the thymidine assay and cell cycle progression 
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based techniques like the flowcytometery, as well as proliferation based measurements like 
the clonogenic assay present good results, cell membrane integrity and mitochondrial 
enzyme function based assays have a significant lag time before the presenting of 
measurable alterations. A successful cellular repair event during this lag time may change 
the final conclusion dramatically. One needs to be aware of these possibilities in 
interpretation of cytotoxicity test results.  Figure 11 represents the measurement of cisplatin 
cytotoxicity effect on MDCK cell line using MTT assay. As is shown in this figure, a 48 hours 
exposure time difference is needed to acquire a reasonable survival curve using this method. 
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Fig. 11. The lag time required to get a good MTT result on the cytotoxicity of cisplatin on 
MDCK cell. 
A discrepancy analysis to measure the cytotoxicity of many of novel anticancer drugs 
developed in our center under the same condition on the same cell line using two different 
methods of clonogenic assay and the neutral red assay, did not show agreement with a clear 
horizontal line and 95% confidence interval of about 1. It would further prove the 
importance of the selection and application of a suitable survival measurement system in 
the analysis of various anticancer candidates. 
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Fig. 12. A comparison of clonogenic versus neutral red assay for the measurement of cell 
survival after exposure to various novel anticancer drugs, using a discrepancy analysis 
method.  
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A good cellular practice on anticancer drugs requires the best selections of cell line and 
model system, the best matched measurement methodology, and the most optimized lag 
time to look at the result for acquiring the most precise and accurate conclusion. 
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